Managed Healthcare Executive3d
Ebglyss Shows Improvement in Atopic Dermatitis Patients Who Stopped Dupixent
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
Promising Outlook for Regeneron Amidst Challenges: Buy Rating Affirmed
Evan Seigerman, an analyst from BMO Capital, reiterated the Buy rating on Regeneron (REGN – Research Report). The associated price target ...
Yahoo Finance12d
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
TARRYTOWN, N.Y. and PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent ...
Regeneron: A Buy Opportunity Amid Short-Term Setbacks and Promising Pipeline Potential
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a ...